NCT02849496: Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer

NCT02849496
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must be HER2-neg AND BRCA+
Exclusions: Patients with known symptomatic central nervous system (CNS) metastases. Patients with asymptomatic untreated CNS disease may be enrolled- see trial for details
https://ClinicalTrials.gov/show/NCT02849496

Comments are closed.

Up ↑